New Autism Drug: Carbetocin
Interview: Christopher McDougle, MD, Chris McDougle, chairman Department of Psychiatry; senior consultant, Christian Sarkine Autism Treatment Center
And now, a new autism medication thatís entering the clinical trial phase.
Chris McDougle, MD, is an autism specialist and professor of psychiatry at the IU School of Medicine. He speaks with Sound Medicineís Dr. David Crabb about the new drug, called carbetocin.
Carbetocin targets the core symptoms of autism, particularly the social impairments and repetitive behaviors associated with this devastating disease. If successful, Dr. McDougle says, carbetocin could revolutionize the treatment of autism.
Dr. Chris McDougle is chair of the Department of Psychiatry at the IU School of Medicine.
Cypress Bioscience is the maker of carbetocin, which is a synthetic version of the hormone oxytocin.
If you'd like details about Dr. McDougle's research, contact the Christian Sarkine Autism Treatment Center: 317-948-9766.